Angelini Pharma has completed its $4.1 billion all-cash acquisition of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), taking the rare-disease drugmaker private and delisting its shares from the Nasdaq. The transaction, which closed on Wednesday, paid shareholders $31.50 per share, a 21% premium over the unaffected closing price from April 22.
Deal Structure and Valuation
The headline equity value of roughly $4.1 billion masks the true cost of the deal due to Catalyst's substantial cash reserves. According to management's preliminary estimate, the company held approximately $861 million in net cash as of June 30, with no funded debt. Subtracting that cash leaves a preliminary enterprise value of about $3.24 billion.
Based on management's forecast of $635 million in revenue for 2026, the acquisition price represents a multiple of roughly 5.1 times anticipated sales. By contrast, the equity-based multiple would have been approximately 6.5 times. The adjustment underscores the importance of considering balance sheet strength when evaluating deal metrics.
Revenue Concentration and Growth
Catalyst's product portfolio is heavily concentrated on two key drugs. Firdapse and Agamree together generated $135.6 million in first-quarter product revenue, accounting for roughly 91% of total product sales. Firdapse, used for Lambert-Eaton myasthenic syndrome, saw sales increase 18.1% year-over-year, while Agamree, approved for Duchenne muscular dystrophy, surged 66.6%.
In contrast, Fycompa revenue declined 61.3% following the loss of exclusivity in 2025. The product mix shift toward higher-growth assets remains a key factor in the company's margin profile.
Margin Improvement and Royalty Tailwind
Operating income for the first quarter rose 15.6%, outpacing the 5.6% increase in product revenue. A significant contributor to this margin expansion is the reduction in Firdapse's upstream royalty rate, which fell to 6% from a previous peak of 18.5%. This adjustment allows a greater share of Firdapse revenue to flow directly to operating earnings, enhancing the attractiveness of the asset for Angelini.
Catalyst's strong cost structure and high-margin product mix were likely key factors in Angelini's decision to acquire the company. The deal provides Angelini with a focused, high-margin growth platform in the rare-disease space.
Management and Strategic Rationale
Rich Daly, Catalyst's former CEO, described the proposal as offering “immediate and certain cash value” to shareholders. Daly has since taken the helm of Angelini's global rare-disease division. Angelini CEO Sergio Marullo di Condojanni called the completion a “decisive step” toward achieving global scale, noting that the acquisition brings three approved medicines and Catalyst's U.S. operations.
With the transaction closed, Catalyst shares were halted on Nasdaq and will cease public reporting following deregistration. Former shareholders are excluded from any future earnings of the now-private entity.
Market Context and Risks
The broader biotech sector saw modest weakness on the day of the deal's completion. The SPDR S&P Biotech ETF (NYSEARCA:XBI) traded 1.3% lower at $152.53 in morning trading.
Investors should note that Angelini faces several risks, including potential reimbursement pressures, generic competition, and integration challenges. Catalyst's proxy statement had previously adjusted certain Firdapse and Fycompa forecasts to reflect concerns about pricing and competitive threats. For rare-disease investors, the true benchmark from this deal is not the $4.1 billion headline, but rather the approximately 5.1 times sales multiple for a business with two profitable products.
